Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02612779 · OUTCOME

Overall Survival (OS)

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. · Source last updated 2021-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From first dose to study completion date (up to approximately 50 months)

What was measured

OS is defined as the time from first dosing date to the date of death from any cause.

Analysis population: All treated participants

Groups in this outcome

EPd Cohort

Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.

EN Cohort

Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EPd Cohort68
EN Cohort6

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
EPd Cohort41.2Not reported22.7NAUpper limit not estimable
EN CohortNANot reported0.6NAThe median was not reached because of an insufficient number of events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Upper limit not estimable
        group Id
        OG000
        lower Limit
        22.7
        upper Limit
        NA
        value
        41.2
      2. comment
        The median was not reached because of an insufficient number of events
        group Id
        OG001
        lower Limit
        0.6
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      68
    2. group Id
      OG001
      value
      6
    units
    Participants
description
OS is defined as the time from first dosing date to the date of death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.
    id
    OG000
    title
    EPd Cohort
  2. description
    Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.
    id
    OG001
    title
    EN Cohort
param Type
MEDIAN
population Description
All treated participants
reporting Status
POSTED
time Frame
From first dose to study completion date (up to approximately 50 months)
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice